drugset / Trial / NCT07408336
Clinical Study of AFN50 Injection in the Autoimmune Diseases
Phase 0
Recruiting
18 enrolled
AlphaNa Bioscience Company Limited
The First Affiliated Hospital of Anhui Medical University · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an investigator-initiated trial designed to evaluate the safety, tolerability and primary efficacy of AFN50 injection for the treatment of autoimmune diseases.
Timeline
- Start
- 2026-02-04
- Primary completion
- 2028-02-04
- Completion
- 2029-02-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AFN50 | Unknown | — | Intravenous |